Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication

J Hepatol. 1999 Feb;30(2):260-4. doi: 10.1016/s0168-8278(99)80072-5.


Background/aims: An involvement of Helicobacter pylori in the development of hepatic encephalopathy in cirrhotic patients has been proposed, but data confirming such an association are lacking. This prospective study aimed to assess whether ammonia levels and indicators of subclinical portosystemic encephalopathy were influenced by H. pylori status in a series of 62 cirrhotic patients. The effects of H. pylori eradication on such parameters were also investigated.

Methods: Fasting blood ammonia levels, mental state, number connection test, flapping tremor, and EEG tracings were recorded at baseline, and in H. pylori-positive patients (as diagnosed by rapid urease test and 14C-urea breath test) these parameters were reassessed 2 months following eradication therapy.

Results: In this series of non-advanced cirrhotic patients, the prevalence of H. pylori infection was 52%. No significant differences were observed between H. pylori+ and H. pylori- cases with respect to fasting venous blood ammonia concentration (47+/-24 vs. 43+/-22 micromol/l) or to the remaining parameters assessing portosystemic encephalopathy. In addition, H. pylori eradication failed to induce any significant variation in either fasting blood ammonia levels (from 45+/-23 to 48+/-26 micromol/l) or neurologic disturbances.

Conclusion: These results indicate that H. pylori infection is not a major contributing factor to either fasting blood ammonia levels or parameters assessing subclinical portosystemic encephalopathy in patients with non-advanced liver cirrhosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Ammonia / blood*
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Ulcer Agents / therapeutic use
  • Clarithromycin / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections / blood*
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy
  • Helicobacter pylori*
  • Hepatic Encephalopathy / microbiology*
  • Hepatic Encephalopathy / physiopathology*
  • Humans
  • Liver Cirrhosis / blood*
  • Liver Cirrhosis / microbiology*
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use


  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Ammonia
  • Clarithromycin
  • Omeprazole